Cantor Fitzgerald Reiterates Overweight on Elevance Health, Maintains $600 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Sarah James has reiterated an Overweight rating on Elevance Health (NYSE:ELV) and maintained a $600 price target.
June 12, 2024 | 4:29 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Sarah James has reiterated an Overweight rating on Elevance Health and maintained a $600 price target, indicating strong confidence in the company's future performance.
The reiteration of an Overweight rating and a high price target of $600 by a reputable analyst suggests positive sentiment and confidence in Elevance Health's future performance. This is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100